Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92790C104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Point72 Asset Management, L.P.
13G
|
5.0% |
8/20/2026
Event 8/19/2026
|
|
| Point72 Asset Management, L.P. | 5.0% | ||
| Point72 Capital Advisors, Inc. | 5.0% | ||
| Steven A. Cohen | 5.0% | ||
|
Kynam Capital Management, LP
13G/A
Amendment 2
|
5.7% |
8/14/2026
Event 6/30/2026
|
|
| Kynam Capital Management, LP | 5.7% | ||
| Kynam Capital Management GP, LLC | 5.7% | ||
| Yue Tang | 5.7% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
3.3% |
8/14/2026
Event 6/30/2026
|
|
| Deep Track Capital, LP | 3.3% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 3.3% | ||
| David Kroin | 3.3% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
6.1% |
8/14/2026
Event 6/30/2026
|
|
| Paradigm BioCapital Advisors LP | 6.1% | ||
| Paradigm BioCapital Advisors GP LLC | 6.1% | ||
| Senai Asefaw, M.D. | 6.1% | ||
| Paradigm BioCapital International Fund Ltd. | 5.3% | ||
| Price T Rowe Associates Inc /MD/ 13G | 5.2% |
8/14/2026
Event 6/30/2026
|
|
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
|
|
Paradigm Biocapital Advisors LP
13G
|
5.1% |
6/26/2026
Event 6/18/2026
|
|
| Paradigm BioCapital Advisors LP | 5.1% | ||
| Paradigm BioCapital Advisors GP LLC | 5.1% | ||
| Senai Asefaw, M.D. | 5.1% | ||
| Paradigm BioCapital International Fund Ltd. | 4.5% | ||
|
Bellevue Group AG
13G
|
6.6% |
5/15/2026
Event 3/31/2026
|
|
| Bellevue Group AG | 6.6% | ||
| Bellevue Asset Management AG | 6.6% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 8
|
14.0% |
5/13/2026
Event 5/11/2026
|
|
| Fairmount Funds Management LLC | 14.0% | ||
| Fairmount Healthcare Fund II GP LLC | 14.0% | ||
|
Deep Track Capital, LP
13G
|
5.3% |
5/8/2026
Event 5/1/2026
|
|
| Deep Track Capital, LP | 5.3% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.3% | ||
| David Kroin | 5.3% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Kynam Capital Management, LP
13G/A
Amendment 1
|
1.5% |
2/17/2026
Event 12/31/2025
|
|
| Kynam Capital Management, LP | 1.5% | ||
| Kynam Capital Management GP, LLC | 1.5% | ||
| Yue Tang | 1.5% | ||
|
Deep Track Capital, LP
13G/A
Amendment 3
|
2.7% |
2/13/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 2.7% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 2.7% | ||
| David Kroin | 2.7% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
3.9% |
11/14/2025
Event 9/30/2025
|
|
| Commodore Capital LP | 3.9% | ||
| Commodore Capital Master LP | 3.9% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 7
|
15.1% |
10/27/2025
Event 10/23/2025
|
|
| Fairmount Funds Management LLC | 15.1% | ||
| Fairmount Healthcare Fund II GP LLC | 15.1% | ||
|
Kynam Capital Management, LP
13G
|
5.8% |
5/15/2025
Event 3/31/2025
|
|
| Kynam Capital Management, LP | 5.8% | ||
| Kynam Capital Management GP, LLC | 5.8% | ||
| Yue Tang | 5.8% | ||
|
Commodore Capital LP
13G
|
5.3% |
4/11/2025
Event 4/4/2025
|
|
| Commodore Capital LP | 5.3% | ||
| Commodore Capital Master LP | 5.3% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 5
|
4.5% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners III, L.P. | 4.5% | ||
| VHCP Co-Investment Holdings III, LLC | 4.5% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 4.5% | ||
| VHCP Management III, LLC | 4.5% | ||
| VHCP Management EG, LLC | 4.5% | ||
| Nimish Shah | 4.5% | ||
| Bong Y Koh | 4.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.39 k | $28.5 k |
| 2026 Q2 | 226 | 138 M | $2.59 B |
| 2026 Q1 | 233 | 112 M | $2.21 B |
| 2025 Q4 | 237 | 108 M | $3.36 B |
| 2025 Q3 | 179 | 93.5 M | $2.02 B |
| 2025 Q2 | 180 | 94.9 M | $1.33 B |
| 2025 Q1 | 187 | 91.4 M | $1.23 B |
| 2024 Q4 | 196 | 91.0 M | $1.75 B |
| 2024 Q3 | 181 | 87.5 M | $1.99 B |
| 2024 Q2 | 154 | 70.1 M | $912 M |
| 2024 Q1 | 152 | 72.5 M | $1.27 B |
| 2023 Q4 | 146 | 61.1 M | $1.33 B |
| 2023 Q3 | 129 | 50.2 M | $770 M |
| 2023 Q2 | 144 | 47.1 M | $1.12 B |
| 2023 Q1 | 151 | 43.1 M | $1.10 B |
| 2022 Q4 | 131 | 43.1 M | $1.26 B |
| 2022 Q3 | 112 | 38.0 M | $779 M |
| 2022 Q2 | 92 | 28.3 M | $328 M |
| 2022 Q1 | 77 | 24.9 M | $461 M |
| 2021 Q4 | 61 | 24.7 M | $488 M |
| 2021 Q3 | 44 | 13.6 M | $224 M |
| 2021 Q2 | 28 | 6.80 M | $124 M |
| 2021 Q1 | 34 | 5.54 M | $84.5 M |
| 2020 Q4 | 2 | 229 k | $3.77 M |